Compare Globus Medical Inc. Class A Common Stock (GMED) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Impinj Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Impinj Inc trades at $189.45 (market cap $5.87B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Impinj Inc is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Impinj Inc for 22 Days on average.
| GMED | PI | |
|---|---|---|
Market Cap | $10.25B | $5.87B |
Volume | 1,059,528 | 471,260.45 |
Sector | Health | Technology |
52-Week High | $96.82 | $241.91 |
52-Week Low | $58.33 | $91.34 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $9.76B | $6.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Impinj (PI) trades at $183.26, down 3.56% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results with EPS of $0.86 beating estimates, though it operates at a net loss margin of -7.26%. Recent news highlights CEO optimism about growth in RFID tracking markets and upcoming Q3 earnings.
Outlook remains mixed: analyst consensus is bullish (73% buy ratings) with a $178.83 price target, but high valuation multiples and persistent losses pose risks. Key catalysts include Q3 earnings and execution in retail and logistics segments, while competition and margin pressure are concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
